Sorafenib in hepatocellular carcinoma: Prospective study on adverse events, quality of life, and related feasibility under daily conditions

Medical Oncology

Volumn 30, Issue 1, 2013, Pages

  Brunocilla, Paola Rita ^a,c   Brunello, Franco ^a   Carucci, Patrizia ^a   Gaia, Silvia ^a   Rolle, Emanuela ^a   Cantamessa, Alessandro ^a   Castiglione, Anna ^b   Ciccone, Giovannino ^b   Rizzetto, Mario ^a  

^a Division of Gastroenterology and Hepatology   (Italy)

^b Institute of Tumor Epidemiology   (Italy)

^c SCDU Gastro Hepatology   (Italy)

Author keywords

Hepatocellular carcinoma; Quality of life; Sorafenib; Targeted therapy

Indexed keywords

SORAFENIB; ANTINEOPLASTIC AGENT; CARBANILAMIDE DERIVATIVE; DRUG DERIVATIVE; NICOTINAMIDE;

ABDOMINAL PAIN; ADULT; AGED; ALOPECIA; ANOREXIA; ARTICLE; BLEEDING; CLINICAL ARTICLE; DIARRHEA; DRUG DOSE REDUCTION; DRUG WITHDRAWAL; FATIGUE; FEMALE; FUNCTIONAL ASSESSMENT; HAND FOOT SYNDROME; HUMAN; HYPERBILIRUBINEMIA; HYPERTENSION; LIVER CELL CARCINOMA; LIVER DYSFUNCTION; MALE; NAUSEA; PRIORITY JOURNAL; PROSPECTIVE STUDY; QUALITY OF LIFE; QUESTIONNAIRE; RASH; SCORING SYSTEM; SIDE EFFECT; SKIN MANIFESTATION; THROMBOCYTOPENIA; VOICE CHANGE; VOMITING; WEIGHT REDUCTION; WELLBEING; CLINICAL TRIAL; LIVER TUMOR; MIDDLE AGED; VERY ELDERLY;

ADULT; AGED; AGED, 80 AND OVER; ANTINEOPLASTIC AGENTS; CARCINOMA, HEPATOCELLULAR; FEMALE; HUMANS; LIVER NEOPLASMS; MALE; MIDDLE AGED; NIACINAMIDE; PHENYLUREA COMPOUNDS; QUALITY OF LIFE; QUESTIONNAIRES;

EID: 84880641414     PISSN: 13570560     EISSN: 1559131X     Source Type: Journal    
DOI: 10.1007/s12032-012-0345-2     Document Type: Article

References (20)

1. Nordenstedt H, White DL, El-Serag HB. The changing pattern of epidemiology in hepatocellular carcinoma. Dig Liver Dis. 2010;42:206-14.
2. Llovet JM, Brù C, Bruix J. Prognosis of hepatocellular carcinoma: the BCLC staging classification. Semin Liver Dis. 1999;19(3):329-38.
3. Bruix J, Sherman M. Management of hepatocellular carcinoma. Hepatology. 2005;42:1208-36.
4. Bruix J, Sherman M. Management of hepatocellular carcinoma: an update. Hepatology. 2011;53(3):1020-2.
5. Abou-Alfa GK, Schwartz L, Ricci S, Amadori D, Santoro A, Figer A, De Greve J, Douillard JY, Lathia C, Schwartz B, Taylor I, Moscovici M, Saltz LB. Phase II study of sorafenib in patients with advanced hepatocellular carcinoma. J Clin Oncol. 2006;24(26):4293-300.
6. Llovet JM, Ricci S, Mazzaferro V, Hilgard P, Gane E, Blanc JF, Cosme de Olivera A, Santoro A, Raoul JL, Forner A, Schwartz M, Porta C, Zeuzem S, Bolondi L, Greten TF, Galle PR, Seitz JF, Borbath I, Häussinger D, Giannaris T, Shan M, Moscovici M, Voliotis D, Bruix J. Sorafenib in advanced hepatocellular carcinoma. N Engl J Med. 2008;359:378-90.
7. Cheng AL, Kang YK, Chen Z, Tsao CJ, Qin S, Kim JS, Luo R, Feng J, Ye S, Yang TS, Xu J, Sun Y, Liang H, Liu J, Wang J, Tak WY, Pan H, Burock K, Zou J, Voliotis D, Guan Z. Efficacy and safety of sorafenib in patients in the Asia-Pacific region with advanced hepatocellular carcinoma: a phase II randomized, double-blind, placebo-controlled trial. Lancet Oncol. 2009;10:25-34.
8. Child CG III, editor. The liver and portal hypertension. Vol. 1 of Major problems in clinical surgery. Philadelphia: W. B. Saunders; 1964. p. 50-64.
9. Pugh RN, Murray-Lyon IM, Dawson JL, Pietroni MC, Williams R. Transection of the esophagus for bleeding oesophageal varices. Br J Surg. 1973;60:646-9.
10. Yount S, Cella D, Webster K, Heffernan N, Chang CH, Odom L, van Gool R. Assessment of patient-reported clinical outcome in pancreatic and other hepatobiliary cancers: the FACT Hepatobiliary Symptom Index. J Pain Symptom Manag. 2002;24(1):32-44.
11. Heffernan N, Cella D, Webster K, Odom L, Martone M, Passik S, Bookbinder M, Fong Y, Jarnagin W, Blumgart L. measuring health-related quality of life in patients with hepatobiliary cancers: the Functional Assessment of Cancer Therapy-Hepatobiliary Questionnaire. J Clin Oncol. 2002;20:2229-39.
12. Trotti A, Colevas AD, Setser A, Rusch V, Jaques D, Budach V, Langer C, Murphy B, Cumberlin R, Coleman CN, Rubin P. CTCAE v3.0: development of a comprehensive grading system for the adverse effects of cancer treatment. Semin Radiat Oncol. 2003;13(3):176-81.
13. Oken MM, Creech RH, Tormey DC, Horton J, Davis TE, McFadden ET, Carbone PP. Toxicity and response criteria of the Eastern Cooperative Oncology Group. Am J Clin Oncol. 1982;5:649-55.
14. Lencioni R, Llovet JM. Modified RECIST (mRECIST) assessment for hepatocellular carcinoma. Semin Liver Dis. 2010;30(1):52-60.
15. Welker MW, Lubomierski N, Gog C, Herrmann E, Engels K, Vogl TJ, Bechstein WO, Zeuzem S, Trojan J. Efficacy and safety of sorafenib in advanced hepatocellular carcinoma under daily practice conditions. J Chemoter. 2010;22(3):205-11.
16. Spinzi G, Terreni N. Health-related quality of life and sorafenib. Hepatology. 2010;52(4):1523.
17. Bukowski R, Cella D, Gondek K, Escudier B. Effects of sorafenib on symptoms and quality of life results from a large randomized placebo-controlled study in renal cancer. Am J Oncol. 2007;30:220-7.
18. Miyake H, Kurahashi T, Yamanaka K, Kondo Y, Takenaka A, Inoue T, Fujisawa M. Impact of sorafenib on health-related quality of life in Japanese patients with metastatic renal cell carcinoma: a prospective evaluation. BJU Int. 2010;106(11):1643-7.
19. Cella D. Beyond traditional outcomes: improving quality of life in patients with renal cell carcinoma. Oncologist. 2011;16(2):23-31.
20. Iyer R, Fetterly G, Lugade A, Thanavala Y. Sorafenib: a clinical and pharmacologic review. Expert Opin Pharmacother. 2010;11(11):1943-55.